Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

BACKGROUND: Copanlisib is a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the α- and δ-isoforms. PATIENTS AND METHODS: This phase II study evaluated the response rate of copanlisib administered intravenously on days 1, 8, and 15 of a 28-day cycle, in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Dreyling, M., Morschhauser, F., Bouabdallah, K., Bron, D., Cunningham, D., Assouline, S. E., Verhoef, G., Linton, K., Thieblemont, C., Vitolo, U., Hiemeyer, F., Giurescu, M., Garcia-Vargas, J., Gorbatchevsky, I., Liu, L., Koechert, K., Peña, C., Neves, M., Childs, B. H., Zinzani, P. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834070/
https://www.ncbi.nlm.nih.gov/pubmed/28633365
http://dx.doi.org/10.1093/annonc/mdx289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834070/
https://www.ncbi.nlm.nih.gov/pubmed/28633365
http://dx.doi.org/10.1093/annonc/mdx289

Ejemplares similares